Pfizer submitted its New Drug Application (NDA) for sildenafil (Viagra) to the FDA in 1997. This detailed application included extensive data from clinical trials demonstrating sildenafil’s efficacy and safety in treating erectile dysfunction. The FDA’s rigorous review process involved a thorough examination of this data, assessing factors such as efficacy, safety, and quality of manufacturing.
Key Aspects of the FDA Review
The FDA’s evaluation focused on several key areas. Scientists carefully analyzed clinical trial results to determine the drug’s effectiveness in improving erectile function compared to a placebo. They scrutinized safety data, looking for adverse events and their frequency. Manufacturing processes were also examined to ensure consistent quality and purity. This rigorous process took several months, including multiple meetings between FDA officials and Pfizer representatives.
Following this intensive assessment, the FDA issued its approval in March 1998, paving the way for Viagra’s launch and widespread availability. The agency’s decision was based on the substantial evidence presented by Pfizer that demonstrated both the efficacy and acceptable safety profile of sildenafil for its intended use. The review process highlighted the FDA’s commitment to a thorough evaluation of new drugs before public release.
